Lonza Group Ltd. (Basel, Switzerland) has officially launched Memree, the company’s new line of phosphatidylserine (PS) products.
Lonza Group Ltd. (Basel, Switzerland) has officially launched Memree, the company’s new line of phosphatidylserine (PS) products. The company anticipated product launches last year, when the company entered into a partnership with PS developer Lipogen Ltd. (Haifa, Israel).
PS is a cognitive health ingredient that has shown potential to improve memory, concentration, and learning in human clinical trials. PS is the only ingredient authorized for a qualified FDA health claim for cognitive dysfunction and dementia in the elderly.
The Memree PS product line includes MemreePS and MemreePlus, a combination of PS and phosphatidic acid that has demonstrated potential to reduce active levels of cortisol, a hormone associated with stress.
Lonza holds rights to market the phosphatidylserine ingredient in food, beverage, supplement, and medical food forms.
Recent animal study finds that Lysoveta may help reduce neonatal brain injury
July 17th 2024A recent animal study found that lysophosphatidylcholine (LPC)-bound omega-3 long-chain polyunsaturated fatty acids (LCPUFAs), marketed as Lysoveta by Aker BioMarine, protected against neonatal hypoxic-ischemic (HI) brain injury in mice.
Synergistic blend of fructooligosaccharide and L-theanine supports memory in recent study
June 10th 2024A recent study found that the combination of fructooligosaccharide (FOS) and L-theanine, marketed as GBL-Memory from Green Bioactives, based in Edinburgh, Scotland was able to support memory in both animals and humans.